cached image

Richard L. Bowen, MD, Medical College of South Carolina

Chief Medical Officer Voyager Pharmaceuticals 
"Richard Bowen"

Mean distance: 106866
Cross-listing: Alzheimer's Tree - Chemistry Tree

BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Liu T, Bowen RL, Wilson AC, et al. (2022) Estropause, Sex Hormones and Metal Homeostasis in the Mouse Brain. Frontiers in Neurology. 13: 841822
Butler T, Goldberg JD, Galvin JE, et al. (2021) Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus cholinesterase inhibition to reduce neurologic decline in Alzheimer's. Contemporary Clinical Trials. 106488
Butler T, Bowen R, Atwood CS. (2019) Septal hypertrophy and cell cycle re-entry in AD. Aging
Smith MA, Bowen RL, Nguyen RQ, et al. (2018) Putative Gonadotropin Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. Journal of Alzheimer's Disease : Jad
Atwood CS, Hayashi K, Meethal SV, et al. (2017) Does the degree of endocrine dyscrasia post-reproduction dictate post-reproductive lifespan? Lessons from semelparous and iteroparous species. Geroscience
Bowen RL, Butler T, Atwood CS. (2016) Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Atwood CS, Bowen RL. (2015) A Unified Hypothesis of Early- and Late-Onset Alzheimer's Disease Pathogenesis. Journal of Alzheimer's Disease : Jad. 47: 33-47
Atwood CS, Bowen RL. (2015) The Endocrine Dyscrasia that Accompanies Menopause and Andropause Induces Aberrant Cell Cycle Signaling that Triggers Re-entry of Post-mitotic Neurons into the Cell Cycle, Neurodysfunction, Neurodegeneration and Cognitive Disease. Hormones and Behavior
Bowen RL, Perry G, Xiong C, et al. (2015) A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. Journal of Alzheimer's Disease : Jad. 44: 549-60
Clark I, Atwood C, Bowen R, et al. (2012) Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacological Reviews. 64: 1004-26
See more...